Mao Nakayama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mao Nakayama has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Akiko Suga
National Institute of Sensory Organs, National Hospital Organization Tokyo Medical Center, Tokyo, Japan
1 shared publication - Chojiro Kimura
Kimura Eye Clinic, Iwaki, Japan
1 shared publication - Daisuke Iejima
National Institute of Sensory Organs, National Hospital Organization Tokyo Medical Center, Tokyo, Japan
1 shared publication - Fumihiko Mabuchi
Department of Ophthalmology, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
1 shared publication - Itaru Kimura
Department of Ophthalmology, Tokai University Hachioji Hospital, Tokyo 192-0032, Japan
1 shared publication - Kazutoshi Yoshitake
National Institute of Sensory Organs, National Hospital Organization Tokyo Medical Center, Tokyo, Japan
1 shared publication
Latest Publications
- Open Access
- 1 November 2022
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (21)
METTL23 mutation alters histone H3R17 methylation in normal-tension glaucoma
Normal-tension glaucoma (NTG) is a heterogeneous disease characterized by retinal ganglion cell (RGC) death leading to cupping of the optic nerve head and visual field loss at normal intraocular pressure (IOP). The pathogenesis of NTG remains unclear. Here, we describe a single nucleotide mutation in exon 2 of the methyltransferase-like 23 (METTL23) gene identified in 3 generations of a Japanese family with NTG. This mutation caused METTL23 mRNA aberrant splicing, which abolished normal protein production and altered subcellular localization. Mettl23–knock-in (Mettl23+/G and Mettl23G/G) and -knockout (Mettl23+/– and Mettl23–/–) mice developed a glaucoma phenotype without elevated IOP. METTL23 is a histone arginine methyltransferase expressed in murine and macaque RGCs. However, the novel mutation reduced METTL23 expression in RGCs of Mettl23G/G mice, which recapitulated both clinical and biological phenotypes. Moreover, our findings demonstrated that METTL23 catalyzed the dimethylation of H3R17 in the retina and was required for the transcription of pS2, an estrogen receptor α target gene that was critical for RGC homeostasis through the negative regulation of NF-κB–mediated TNF-α and IL-1β feedback. These findings suggest an etiologic role of METTL23 in NTG with tissue-specific pathology.
- 1 November 2022
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (21)
Open AccessMETTL23 mutation alters histone H3R17 methylation in normal-tension glaucoma
Normal-tension glaucoma (NTG) is a heterogeneous disease characterized by retinal ganglion cell (RGC) death leading to cupping of the optic nerve head and visual field loss at normal intraocular pressure (IOP). The pathogenesis of NTG remains unclear. Here, we describe a single nucleotide mutation in exon 2 of the methyltransferase-like 23 (METTL23) gene identified in 3 generations of a Japanese family with NTG. This mutation caused METTL23 mRNA aberrant splicing, which abolished normal protein production and altered subcellular localization. Mettl23–knock-in (Mettl23+/G and Mettl23G/G) and -knockout (Mettl23+/– and Mettl23–/–) mice developed a glaucoma phenotype without elevated IOP. METTL23 is a histone arginine methyltransferase expressed in murine and macaque RGCs. However, the novel mutation reduced METTL23 expression in RGCs of Mettl23G/G mice, which recapitulated both clinical and biological phenotypes. Moreover, our findings demonstrated that METTL23 catalyzed the dimethylation of H3R17 in the retina and was required for the transcription of pS2, an estrogen receptor α target gene that was critical for RGC homeostasis through the negative regulation of NF-κB–mediated TNF-α and IL-1β feedback. These findings suggest an etiologic role of METTL23 in NTG with tissue-specific pathology.